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ABSTRACT: It is known that aziridines and nitrogen mustards exert their biological activities, 
especially in chemotherapy, via DNA alkylation. The studied scaffold, 2-phenyl-1-aziridine, 
provides a distinct conformation compared to commonly used aziridines, and therefore, leads to 
a change in high-strained ring reactivity towards biological nucleophiles, such as DNA. The 
above series of compounds was tested in three breast cell lines: MCF-10, a healthy cell; MCF-7, 
a hormone responsive cancer cell; and MDA-MB-231, a triple negative breast cancer cell. Both 
aziridines and their precursors, β-amino alcohols, showed activity towards these cells, and 
some of the compounds showed higher selectivity index than cisplatin, the drug used as control. 
When the type of cell death was investigated, the synthesized compounds demonstrated higher 
apoptosis and lower necrosis rates than cisplatin, and when the mechanism of action was 
studied, the compounds were shown to interact with DNA via its minor groove instead of 
alkylation or intercalation.  
1.Introduction 
Targeting DNA and drug-DNA interactions has been of great importance since the 
second half of the 20th century.1 Small molecules can interfere with the DNA functions 
either by modulating transcription or by interfering with cell growth and replication as 
inhibitors.2 Although they have been studied for decades, the mechanisms of DNA-drug 
interactions are still not fully comprehended.  
There are two main modes of drug-DNA binding.3 The covalent type found in alkylating 
agents may act via three mechanisms:4 irreversible covalent binding with guanine 
(such as cisplatin and aziridines); cross-link formation between atoms of DNA (two 
bases are linked by an alkylating agent that has two binding sites, such as nitrogen 
mustards); and nucleotide mispairing, resulting in a mutation by covalent interaction, 
and consequently leading to apoptosis;5 The non-covalent binding involves 
intercalation and minor groove binders. The first one is found in planar organic 
compounds and act by π-π stacking between DNA base pairs and the aromatic portion 
of the molecule. This leads to structural changes in the DNA itself, because 
intercalation can unwind the DNA double helix. 4  
Minor groove binders are small molecules, usually in a crescent-like shape (Figure 1), 
that interact by Van der Waals interactions and hydrogen bonds in the minor groove of 
the DNA double strand.1, 3, 6 They typically have several heterocyclic aromatic rings and 
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are commonly employed to bind to specific adenine-thymine (AT)-rich sequences. 
Netropsin, a polyamide with antibiotic and viral properties, and pyrrole-imidazole 
polyamides are examples of DNA-binding agents.  
 
Figure 1. Crescent-like shape molecules used as minor groove binders 
Minor groove binders are also used in chemotherapy in several types of cancer, such 
as carcinoma and ovary and breast cancer (BRCA).7 Among them, the latter is the 
most prevalent type of cancer in women worldwide, representing 12% of all new cases 
of cancer and 25–30% of all cancers in women.8, 9 According to the American Cancer 
Society, in the USA alone, approximately 266,120 (30% of all) new cases of invasive 
breast cancer will be diagnosed in women and more than 41,400 (14%) women are 
estimated to die in 2018 from it.10 BRCA is a heterogenous disease in which multiple 
subtypes are identified—each one showing distinctive profiles of prognosis, 
physiopathology, and treatments. 
Several BRCA subtypes present well established therapy guidelines such as the use of 
hormonal adjuvant treatment in hormone-sensitive cancers to block estrogen effects for 
estrogen- (ER) and progesterone-positive (PR) cancers.10 When the subtype is PR and 
ER negative but HER2 positive, monoclonal antibodies and tyrosine kinase inhibitors 
(such as trastuzumab and lapatinib, respectively) are effective.11, 12 When 
immunohistochemical analysis shows no hormone receptors on breast cancer cell and 
the cell is HER2 negative, it is called triple negative breast cancer (TNBC). TNBC 
accounts for 15–20% of all cases. 13  Although TNBC is primarily treated with 
chemotherapy, the lack of specific molecular targets leads to low efficacy, consequently 
leading to a difficult, more aggressive, and less effective treatment. TNBC usually leads 
to poor prognosis and a high propensity for metastasis progression and chemotherapy 
resistance.13 Since there are no targeted therapies specifically for this type of cancer, 
cytotoxic chemotherapy remains the best option to date.14 Alkylating-like agents such 
as platinum derivatives associated with doxorubicin and bevacizumab are used for the 
treatment of TNBC.15-17 
In this work, as part of our continuous efforts to find cytotoxic antitumor candidates, we 
herein report the discovery of aziridine and β-amino alcohol minor-groove binders 
possessing cytotoxicity against TBNC cells. First, we synthetized both β-amino 
alcohols and their correspondent azidirines and evaluated their biological activity 
towards healthy and cancer cell lines. Then, since the compounds presented activity 
and selectivity, we studied the mechanism of action by flow cytometry and drug-DNA 
interactions, which demonstrated a non-conventional mechanism of action. Finally, we 
compared these results to molecular docking, which corroborated the experimental 
results. 
 
2. Results and discussion 
2.1 Chemistry  
. The synthesis of 2-phenyl-1-aziridine series 5a-d involved intramolecular cyclization of the 
corresponding β-amino alcohol 3, which was prepared by aminolysis of the epoxide starting 
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material, via a modified Wenker synthesis18-20 (Scheme 1). This strategy facilitated the 
development of a homologue series of N-substituted side chain to study the influence of the 
length of alkyl chain between each of the aromatic portions in both amino alcohols and 
aziridines towards the presented biological activity.  
Initially, amino alcohols 3a-h were obtained by ring-opening of styrene oxides (1a and 1b) using 
several amines (2a-g) in a solvent-free methodology. Since aminolysis is not regiospecific, both 
the regioisomers were obtained, which were easily separated by crystallization or 
chromatography. Then, the desired amino alcohol was allowed to react with chlorosulfonic acid 
or sulfuryl chloride to produce the corresponding sulfonyl esters 4a-d. Finally, after treatment of 
sulfonyl esters with a base, aziridines were successfully synthesized in varying yields (35–70% 
in a 1 mmol scale).  
 
Scheme 1. Synthetic approach for compounds of interest. Conditions: (A) 200°C, 4 h or room temperature  (r.t) 
H2O, 6 h (when aniline is used); (B) 1, 2 eq. ClSO3H or SO2Cl2, 0°C, Et 2O/DCM; (C) NaOH 6 M/toluene (10:1), 
100°C, 18 h 
2.2 Biological evaluation 
The small library of amino alcohols and respective aziridines were screened against the 
following targets: i) healthy breast tissue MCF-10; ii) hormone-responsive breast cancer MCF-; 
and iii) TNBC cell line MB-231. Their half maximal inhibitory concentration (IC50), LD50, and 
selectivity index (SI) are shown in Table 1. The MTT assays were conducted by following the 
Mosmann methodology21. The cytotoxicity of the studied compounds was compared with 
cisplatin, which is a drug prescribed for several types of breast cancers and an alkylating-like 
agent. Based on the results shown in Table 1, some compounds of the two classes studied 
presented higher selectivity towards cancer cell lines than cisplatin, and higher SI. However, 
cisplatin showed lower toxicity (higher CC50). It was observed that the longer the alkyl chain 
between the aromatic rings (from methyl to butyl—as seen in scheme 1), the higher the activity 
in both amino alcohols and aziridines. Furthermore, a difference in selectivity between β-amino 
alcohols and their corresponding aziridines was observed. In the MCF7 cell line, β-amino 
alcohols presented a higher SI, while aziridines showed higher activity and SI towards the MB-
231 cell line. 
MB-231 cell line was of special interest because of the lack of therapeutic drugs with high SI or 
efficacy for the long-term treatment of TNBC. The synthetized compounds presented cytotoxic 
effects, especially the longest alkyl chain β-amino alcohol 3d and its respective aziridine 5d, 
when compared to cisplatin in terms of both IC50 (50.76, 11.09, and 78.14 µM, respectively) and 
SI (2.11, 4.08, and 0.92, respectively). Aziridines 5a, 5b, and 5c also showed higher activity 
than cisplatin, but with a higher IC50 (40.42, 19.00, and 19.8 µM) and lower SI (1.01, 1.97, and 
1.77). In addition, 3f presented a high activity comparable to aziridines, indicating that a minor 
change in one of the aromatic moieties can lead to an increase in activity. These same 
compounds presented higher activity than cisplatin against the MCF-7 cell line. However, β-
amino alcohols with longer chains presented a higher SI (2.02, 2,88, 4.04, and 2.18 for 3c, 3d, 
3f and 3g, respectively, whereas cisplatin showed a value of 1.45), although they did not 
necessarily present the best values for IC50. 
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Table 1: Anti-tumor activity (IC50), cytotoxicity (CC50), and selectivity indices (SI) of the 
compounds.  
 
Compounds 
 
 
IC50MCF-7 (µM) IC50 MDA-
MB231(µM) 
CC50 MCF-10(µM) SIMC
F-7 
SIMDA-
MB231 
3a 209.60 ± 3.10 225.30 ± 3.85 201.60 ± 4.45 0.96 0.89 
3b 318.50 ± 0.45 189.90 ± 5.9 197.50 ± 5.40 0.62 1.04 
3c 96.40 ± 2.77 101.80 ± 1.79 195.60 ± 0.75 2.02 1.92 
3d 37.17 ± 1.34 50.76 ± 2.47 107.30 ± 4.7 2.88 2.11 
3e 279.60 ± 1.5 259.40 ± 4.17 187.70 ± 5.76 0.67 0.72 
3f 14.48 ± 0.61 22.71 ± 0.21 58.54 ± 1.33 4.04 2.57 
3g 53.01 ± 2.66 73.89 ± 3.12 115.60 ± 0.95 2.18 1.56 
3h 236.20 ± 5.35 236.90 ± 4.92 316.16 ± 4.85 1.33 1.33 
5a 27.83 ± 0.42 40.42 ± 1.34 40.99 ± 0.25 1.47 1.01 
5b 169.70 ± 5.99 19.00 ± 0.90 37.57 ± 1.5 0.2 1.97 
5c 24.50 ± 1.11 19.89 ± 2.23 35.43 ± 1.31 1.44 1.77 
5d 24.72 ± 0.5 11.09 ± 0.39 43.30 ± 0.03 1.83 4.08 
Cisplatin 49.26 ± 0.21 78.14 ± 2,4 72.14 ± 4.12 1.45 0.91 
 
 
2.3 Mechanism of action investigation  
Since compounds 3d, 3f, and 5d showed high tumorigenic activity, especially against 
the MB-231 cell line, they were selected for further studies to elucidate the mechanism 
by which they induced cell death. In a simple approach, the detection of externalization 
of phosphatidylserine was performed by staining with Annexin V/propidium iodide (PI) 
(Figure 2A) via flow cytometry. Both 3f- and 5d-treated MB-231 cells induced apoptosis 
above 75% of MB-231 population (3f = 91.3% and 5d = 77%, Figure 2B). The 
percentage of early apoptotic cells (Annexin V simple stain) was higher in 3f-treated 
cells (33.6%; Figure 2C). Notably, 5d treatment resulted in late apoptosis/necrosis in 
the cells (Annexin V/PI stained) (Figure 2D). This result was in agreement with MTT 
results and suggests that 3f and 5d are cytotoxic to cancer cells, and they probably 
induced apoptosis by different mechanisms. 
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Figure 2. Phenyl aziridines selectively lead to apoptosis of breast tumor cells. Representative dot plot of each 
compound (A). Treatment with 3f and 5d showed higher tumorigenicity (B). 3f treatment led to early apoptosis 
(C). 5d and 3f together showed the same ability to lead to late apoptosis/necrosis (D). Results are presented as 
the mean of triplicate experiments. 
 
Based on the results of flow cytometry assay, we aimed to investigate the mechanism 
of action of these compounds and why they direct cell death to a different direction 
when compared to cisplatin. Although it is known that nitrogen mustards and aziridines 
act as electrophiles for biological nucleophiles such as nitrogenous bases in the DNA, 
we were not sure whether the same mechanism would apply for the compounds tested 
in this study because of the electronic and conformational differences between the 
different types of compounds. 
 
It is well documented in literature that polymethylene analogs of drug candidates can 
enhance biological activity.22, 23 This can be caused either by increasing the interaction 
with active site or by altering the physicochemical properties related to hydrophobicity, 
such as partition coefficient, solubility in water, and critical micelle concentration. This 
effect seems to be corroborated by the cancer activity results obtained in the present 
study. To investigate this result further, we performed an assay to probe the potential 
interaction between DNA and the studied structures (full experimental details of ct-DNA 
interaction experiment in the experimental procedure). Based on the results obtained in 
the cancer cells, two compounds, 3d and its respective aziridine 5d, were chosen to 
study the potential interaction with DNA. These two molecules have the longest alkyl 
chain between the aromatic moieties tested and the highest activities when there are 
no substituents in the aromatic ring. 3d and 5d were incubated with ct-DNA in buffer 
solution at 32°C for 5 min before recording each electronic spectrum. The binding 
constant (Kb) for each compound-DNA adduct was obtained using the Benesi-
Hildebrand equation (see supplementary information) to verify the relative strength of 
interaction of 3d and 5d with DNA.  
Depending on the type of interaction with DNA, ultraviolet (UV)-visible spectra exhibited 
distinct profile changes. Compounds that bound through intercalation exhibited 
hypochromism on the DNA band centered at 260 nm. To intercalate, the compound 
must have a planar and rigid structure, which is usually provided by the presence of 
fused aromatic rings. 24-26 In contrast, hyperchromic effect in DNA absorption indicates 
the changes in the secondary structure of double helix, which in turn exposes the 
nitrogenous bases to the solvent, thereby increasing the absorption of these 
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chromophores. This kind of change may arise from covalent, groove, or electrostatic 
binding.18 It is rather difficult to distinguish them exclusively based on 
spectrophotometric titration. However, previous studies have reported that a 
combination of hyper-and hypsochromism indicates a covalent interaction such as 
alkylation, while hyperchromism alone is observed when a non-covalent binding takes 
place.17-21 As seen in Figure 4, both 3d and 5d caused hyperchromism in absorption 
band of DNA at 260 nm following DNA-compound interaction, without any 
hypsochromic or bathchromic changes.4, 25, 27  
 
Figure 4. UV-Vis spectra of (A) 3d (10-6 mol L-1) and (B) 5d (1,25x10-8 mol L-1) with increasing concentrations of 
ct-DNA (from 4.9x10-5 to 4.9x10-4 mol L-1) in Tris buffer (5 mM tris(hydroxymethyl)aminomethane hydrochloride 
(Tris), 50 mM NaCl, pH 7.4). Insert: double reciprocal Benesi-Hildebrand plot.  
 
Owing to this observation, it is suggested that minor groove binding is a more favorable 
type of interaction.24 This kind of weak interaction is typical for structures bearing 
unfused aromatic rings, such as phenyl groups of 3d and 5d, bound to flexible carbon 
chains, which have torsional freedom.20 These features present in the molecules under 
investigation in this study, leads to accommodation in the minor groove of DNA, which 
might be directed by hydrophobic interaction, hydrogen bonding, and/or electrostatic 
interactions. Usually minor groove binding is preferred to major groove binding owing to 
a closer in-space interaction of the former and steric hindrance of the latter due to the 
presence of the amine group on C2 of guanine.20 Presumably, in our case, the 
interaction of both species are hydrophobic in nature because of their relatively long 
alkyl chain. In the case of compound 3d, it is reasonable to assume the assistance of 
hydrogen bonds, since this compound bears OH and NH groups in its structure. These 
assumptions are corroborated by the docking results (vide infra). Finally, if DNA is 
assumed to be the target responsible for the observed cytotoxicity, the different kinds of 
interactions of 3d and 5d (groove binding) when compared to cisplatin (alkylation) is 
probably responsible for triggering different mechanisms of cell death.  
The Kb values observed in this study (3d Kb = 1,592 x 105, and 5d Kb = 5,233 x 105) 
are consistent with data reported earlier from similar spectrophotometric titration, 
suggesting a strong interaction between 3d and 5d with ct-DNA.25 To confirm the 
binding mode in DNA, molecular docking was performed for the most active 
derivatives. Autodock 4.2 software was used for calculations, and the Lamarckian 
Genetic Algorithm was selected as a search method.28 Ligands were constructed using 
Spartan 10 WAVEFUNCTION, and Merck Molecular Force Field (MMFF) was applied 
for conformer distribution. The charges were calculated using PM6 following the 
density functional theory (DFT) method.  
 
 
2.4 Molecular docking validation  
Molecular docking validation was performed in two steps. First step 1 (VS 1) was 
performed using re-docking of netropsin in all DNA structures, checking whether the 
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selected parameters were able to identify the correct region of interaction. Netropsin 
was selected for docking validation as it is a well-known minor groove ligand. In 
validation step 2 (VS 2), a reduced grid box was applied to perform a more accurate 
assessment of interactions with the DNA region. 
The parameters used in docking validation, which considered all DNA, were able to 
produce most of the conformational states of netropsin bound in the minor groove, as 
expected. The binding region at the minor groove was rich in A-T base pairs and was in 
accordance with the known binding mode. After identification of the binding region, 
calculations were focused in the minor groove region. The best conformer presented a 
predicted binding energy of -7.74 kcal/mol. This binding mode was similar to the 
binding mode obtained by Ricci et al. for netropsin docking29. 
The best parameter set was applied in the molecular docking of Hoechst-33258 (minor 
groove binder), 3d, 3f, 5a, and 5c derivatives. 
An additional evaluation of the method was executed using Hoechst-33258, a DNA 
inhibitor that binds at the minor groove region. 30 Results showed that parameters of 
both VS 1 and VS 2 were able to identify the correct region of binding as well as the 
correct AT-rich region of binding. Molecular re-docking focusing on minor groove 
returned the conformer with a predicted binding energy of -4.80 kcal/mol (SM). 
The molecular docking of 3f was performed using both methods, and the results 
showed that the minor groove was the preferred region of binding, which was in 
accordance with the experimental assays (Figure 4). This amino alcohol derivative (3f) 
showed interactions with AT-rich region, and the best conformer exhibited a predicted 
binding energy of -8.51 kcal/mol. The proximity of the aromatic ring of the ligand and 
DNA backbone suggests interactions between these groups (Figure 5). 3f is also 
involved in one hydrogen bond with the backbone at regions DA19 and DT18, besides 
a hydrogen bond with thymine of the DT18 base pair (Figure 5b). Although this 
interaction profile was not very common for inhibitors that interact with the minor 
groove, the role of ligand-DNA backbone interactions could be important for elucidating 
the mechanism of action. Interactions between ligands and the sugar atoms of DNA 
backbone could promote stabilization of the complex31. 
The proximity of the aromatic ring of the ligand and the sugar atoms of DNA backbone 
is not exclusive to 3f derivative. Other derivatives also showed this profile, suggesting 
interactions between these atoms of the DNA. The best conformer of this derivative 
showed a predicted binding energy of -8.42 kcal/mol. The derivatives 5a and 5c 
interact mainly through hydrophobic interactions with DNA (Figure 5c-d). Consequently, 
their predicted energies of binding were poorer than 3d and 3f derivatives. The 
predicted binding energies for 5a and 5c were -3.96 and 5.36 kcal/mol, respectively. 3d 
derivative showed two hydrogen bonds with the DNA backbone at DT6 and DA7 
regions, besides one hydrogen bond with thymine of the DT6 base pair (Figure 5e). 
These results corroborated the experimental tests and provided a new insight of how β-
amino alcohols and aziridines can interact with DNA and the importance of an aromatic 
moiety in the scaffold. 
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Figure 5. Molecular docking showing minor groove binding in AT-rich regions (A) of derivatives 3f (B), 5a (C), 
5c (D) and 3d (E). 
 
3. Conclusion 
In conclusion, we synthesized amino alcohols 3a-h and 2-phenyl-1-aziridine series 5a-
d and biologically evaluated these compounds. The results of this study provide new 
insights into the mechanism of action of β-amino alcohols and 2-phenyl-N-alkyl 
aziridines and their interaction with DNA, especially in two breast cancer cell lines. The 
mechanism of action was found to be spatial conformation, leading to a crescent-like 
shaped molecule, although they are small molecules. Moreover, the new compounds 
were more selective than cisplatin in both the cell lines and may provide evidence for 
further studies on new therapies for TNBC. 
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4. Experimental session 
4.1 Chemistry 
4.1.1 General information 
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1H and 13C NMR NMR spectra were determined on a BRUKER® Fourier300 – Ultra 
Shield® spectrometer in CDCl3 or DMSO-d6.  The reagents were all analytical grade or 
chemically pure acquired from Sigma-Aldrich. Flash chromatography was performed on 
silica gel (60Å, 230-400mesh, 40-63µm). 
 
4.1.2 General procedure for synthesis of the β-aminoalcohols 
Epoxide (1a-b, 2 mmol, 1 eq) was slowly added during 1 hour to the amine (4mmol, 
2eq) in a round-bottom flask in reflux. After the addition was completed, the reaction 
mixture was stirred at the amine boiling point for 3h and then cooled to room 
temperature. The oily product solidified over time and was recrystallized in 
dichlorometane-hexane (2:8). When necessary, an additional purification was carried 
out in a short flash chromatography column (Ethyl Acetate-Methanol). 
2-(benzilamine)-1-phenylethan-1-ol (3a) 
 White crystals, 55% yield. 1H RMN (300 MHz, MeOD) δ 7,39 – 7,16 (m, 10H), 4,77 
(dd, J = 8,5, 4,5 Hz, 1H), 3,78 (dt, J = 22,2, 7,7 Hz, 1H), 2,86 – 2,65 (m, 2H).13C NMR 
(75 MHz, MeOD) δ 144,60; 140,5; 129,5; 129,4; 128,5; 128,3; 127,0; 73,4; 57,4; 54,2. 
 
2-(phenetilamine)-1-phenyletan-1-ol (3b) 
 White crystals, 54% yield. 1H RMN (300 MHz, CDCl3) δ 7,34 – 7,10 (m, 10H), 4,74 
(dd, J = 9.4, 3.4 Hz, 1H), 2,92 – 2,84 (m, 2H), 2,83 – 2,76 (m, 2H), 2,75 – 2,67 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 142,1; 142,0; 139,1; 128,8; 128,6; 128,5; 127,7; 126,5; 
125,8; 71,2; 56,6; 50,5; 35,7. 
 
1-phenyl-2-((3-phenylpropyl)amino)ethan-1-ol (3c) 
 White crystals,42% yield. 1H RMN (300 MHz, CDCl3) δ 7,42 – 7,00 (m, 10H), 4,66 (dd, 
J = 8,5; 4,5 Hz, 1H), 2,65 (t, J = 6.,7 Hz, 2H), 2,62 – 2,50 (m, 4H), 1,73 (dt, J = 15,1; 
7,5 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 147,1; 145,6; 131,9; 131,9; 131,1; 129,5; 
129,4; 75,8; 60,6; 37,0; 34,8 
 
1-phenyl-2-((4-phenylbutyl)amino)ethan-1-ol (3d) 
Yellow solid, 45% yield. 1H RMN (300 MHz, MeOD) δ 7,44 – 6,89 (m, 10H), 4,68 (dd, J 
= 7,8; 5,3 Hz, 1H), 2,69 (dd, J = 7,9; 4,8 Hz, 2H), 2,57 (ddd, J = 14,7; 10,0; 5,2 Hz, 4H), 
1,64 – 1,41 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 142,2; 128,5; 128,5; 128,4; 127,7; 
125,9; 77,1; 71,1; 56,7; 49,1; 35,7; 29,0; 28,8. 
 
2-(butylamino)-1-phenylethan-1-ol (3e) 
Yellow solid, 42% yield.1H RMN (300 MHz, CDCl3) δ 7,36 – 7,12 (m, 5H), 4,92 (dd, J = 
9,8; 2,9 Hz, 1H), 2,88 (ddd, J = 5,96; 11,3; 4,8 Hz, 2H), 2,72 (tdd, J = 11,9; 7,8; 4,3 Hz, 
2H), 1,28 (dt, J = 15,0; 7,4 Hz, 4H), 0,76 (t, J = 7,4 Hz, 3H) 13C NMR (75 MHz, CDCl3) 
δ 141,7; 128,8; 127,7; 125,8; 70,5; 65,9; 48,8; 31,4; 20,3; 13,8.  
 
1-(4-bromophenyl)-2-((4-phenylbutyl)amino)ethan-1-ol (3f) 
Yellowish solid, 15% yield. 1H RMN (300 MHz, CDCl3) δ 7,64 – 6,97 (m, 14H), 5,08 
(dd, J = 10,0; 2,5 Hz, 1H), 3,07 – 2,97 (m, 1H), 2,95 – 2,77 (m, 3H), 2,63 (dt, J = 15,0; 
5,6 Hz, 3H), 1,84 – 1,60 (m, 5H). 13C NMR (75 MHz, CDCl3) δ 141,6; 140,0; 131,7; 
128,4; 128,3; 127,5; 126,0; 121,9; 69,4; 55,7; 48,7; 35,4; 28,6; 27,1. 
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2-(benzylamino)-1-(4-bromophenyl)ethan-1-ol (3g) 
Yellow solid, 10% yield. 1H RMN (300 MHz, DMSO) δ 7,50 – 7,27 (m, 9H), 4,65 (t, J = 
6,1 Hz, 1H), 3,73 (d, J = 2,7 Hz, 2H), 2,61 (d, J = 6,2 Hz, 2H). 13C NMR (75 MHz, 
DMSO) δ 143.9, 140.3, 130.7, 128.1, 128.1, 127.9, 126.6, 119.7, 70.7, 56.5, 52.5. 
 
1-phenyl-2-(phenylamino)ethan-1-ol (3h) 
Orange oil, 70% yield. 1H RMN (300 MHz, CDCl3) δ 7,49 – 6,50 (m, 10H), 4,53 (dd, J = 
6,9; 4,2 Hz, 1H), 3,95 (dd, J = 11,1; 4,2 Hz, 1H), 3,76 (dd, J = 11,1; 7,0 Hz, 1H). 13C 
NMR (75 MHz, CDCl3) δ 146.1, 139.4, 129.1, 128.8, 128.6, 127.7, 126.9, 118.7, 114.7, 
77.4, 77.0, 76.6, 66.9, 60.8. 
 
 
4.1.3 – General procedure for the synthesis of aziridines 
To a solution of 3 (1mmol) in ethyl ether/dichlorometane (8:2) at 0°C , chlorossulfonic 
acid or sulfonyl chloride was slowly added (1.2mmol). After stirring at 0°C for 1h, the 
reaction mixture was stirred at room temperature for 2h30. The resulting white solid 
was washed and filtered using 0°C ethyl ether (3x10 ml), isopropyl alcohol (3x10ml) and 
ethyl ether (3x10ml) and was dried under low pressure, resulting in 4(a-d) in 
quantitative yields. To a solution of 4 (a-d - 1mmol) in toluene (5ml), NaOH of 6,2M 
(4,96g in 20ml) was added and the reaction was refluxed for 18h. The reaction mixture 
was then extracted with ethyl acetate (3x20ml), dried over Na2SO4 and the solvent was 
evaporated.  The resulting oil was purified over deactivated silica gel (1% Et3N) in 
hexane: ethyl acetate. The purified compounds were kept under refrigeration and 
covered from light. 
1-benzyl-2-phenylaziridine (5a) 
 Incolor oil, 55% yield. 1H RMN (300 MHz, CDCl3) δ 7,50 – 7,15 (m, 10H), 3,72 (d, J = 
13,7 Hz, 1H), 3,63 (d, J = 13,8 Hz, 1H), 2,53 (dd, J = 6,5; 3,4 Hz, 1H), 2,01 (d, J = 3,3 
Hz, 1H), 1,88 (d, J = 6,5 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 140.1, 139.1, 128.3, 
128.3, 127.8, 126.9, 126.9, 126.2, 64.7, 41.5, 37.9. 
 
1-phenethyl-2-phenylaziridine (5b) 
 Incolor oil, 60% yield. 1H RMN (300 MHz, CDCl3) δ 7,46 – 7,12 (m, 10H), 2,94 (t, J = 
7,6 Hz, 2H), 2,68 (m, J = 11,4; 7,4 Hz, 2H), 2,30 (dd, J = 6,5; 3,4 Hz, 1H), 1,92 (d, J = 
3,4 Hz, 1H), 1,67 (d, J = 6,6Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 140,2; 140,0; 128,8; 
128,3; 128,2; 127,1; 126,1; 126,0; 63,3; 41,4; 37,9; 36,4. 
 
2-phenyl-1-(3-phenylpropyl)aziridine (5c) 
Incolor oil, 50% yield. 1H RMN (500 MHz, CDCl3) (300 MHz, CDCl3) δ 7,36 – 7,13 (m, 
10H), 2,76 – 2,70 (m, 2H), 2,54 (dt, J = 11,6; 7,2 Hz, 1H), 2,44 – 2,33 (m, 1H), 2,31 
(dd, J = 6,5; 3,3 Hz, 1H), 1,98 (dd, J = 15,5; 7,1 Hz, 2H), 1,91 (d, J = 3,4 Hz, 1H), 1,67 
(d, J = 6,5 Hz, 1H). ). 13C NMR (75 MHz, CDCl3) δ 142,2; 140,4; 128,5; 128,4; 128,4; 
126,9; 126,2; 125,8; 61,1; 41,4; 37,8; 33,7, 31,4. 
 
2-phenyl-1-(4-phenylbutyl)aziridine (5d) 
Incolor oil, 65% yield.1H RMN (300 MHz, CDCl3) (300 MHz, CDCl3) δ 7,49 – 6,82 (m, 
10H), 2,65 (t, J = 7,3 Hz, 2H), 2,51 (dt, J = 11,7; 6,8 Hz, 1H), 2,44 – 2,35 (m, 1H), 2,31 
(dd, J = 6,5; 3,3 Hz, 1H), 1,90 (d, J = 3,2 Hz, 1H), 1,81 – 1,70 (m, 4H), 1,67 (d, J = 6,6 
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Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 142,4; 140,4; 128,4; 128,2; 126,8; 126,2; 125,6; 
61,6; 41,2; 37,8; 35,8; 29,4; 29.2. 
 
 
4.2 MTT assay 
The cytotoxity was assessed using the classical [3 – (4,5-dimethylthiazol-2-yl) -2,5-
diphenyl tetrazolium bromide] (MTT) colorimetric assay16. To this end, 5.0 x 105 cells 
(MCF-10, MCF-7 and MDA-MB231) were incubated for 24 hours in 96-well cell culture. 
After this incubation period, the compounds or cisplatine was added (concentrations 
500 to 3.9 µM in serial dilution / compounds solubilized in DMSO 0,5%) in a final 
volume of 200 µL. Cells were incubated for 48 hours at 37 °C.  Aft er incubation with the 
compounds, the medium was removed and added 50 µL of MTT (2.0 mg/mL) diluted in 
phosphate buffered saline (PBS). The precipitated blue MTT formazan was then 
dissolved in 50 µL of DMSO, and the absorbance was measured at 570 nm in a 
VARIAN CARY-50 plate reader MPR multiwell. Cell viability was expressed as the 
percentage of absorption values in treated cells compared with untreated (control) 
cells. IC50 curve fitting was carried out using GraphPad Prism 5 Software (GraphPad 
Software Inc., San Diego, CA). 
 
 
4.3 Flow cytometry assay 
To evaluate the apoptosis events, MDA-MB-231 cells were seeded in 12-well plates at 
5.0 x 106 cells/well for 24 h. Next, they were treated with 3f and 5d compounds or 
cisplatin as positive control for 48 h. After, the cells were trypsinized, washed with ice-
cold PBS and re-suspended in binding buffer, according to the kit instructions. The 
cells were then incubated with FITC-conjugated Annexin V (1:100) for another 15 min 
as recommended by FITC Annexin V Apoptosis Detection Kit (BD Pharmigen ™). 
Propidium iodide (1 µg/mL) was added immediately before BD FAXCANTO™ flow 
cytometer analysis. The excitation/emission used for FITC- conjugated Annexin V was 
494/518 nm while to propidium iodide, the excitation/emission was 585/617 nm. A total 
of 10,000 events were counted per sample and analyzed by the software BD 
FACSDIVA (BD Biosciences).  
 
4.4 DNA samples and binding experiments 
Calf-thymus deoxyribonucleic acid (ct-DNA) was obtained from Sigma-Aldrich. It was 
used as received and stored below 277 K. Ct-DNA was dissolved in a buffer solution (5 
mM tris(hydroxymethyl)aminomethane trishydrochloride (Tris), 50 mM NaCl, pH 7.4) 
and stirred for about 12 hours. The resulting solution of ct-DNA gave ratios of UV 
absorbance at 260 and 280 nm, A260/A280, in between 1.8-1.91, suggesting that the ct-
DNA was sufficiently free of proteins. In this case, the ratio of A260/A280 was 1.86. The 
concentration of nucleic acid solutions was determined spectrophotometrically, using  
= 6600 M-1 cm-1 at 260 nm and it was expressed in terms of base-pair equivalents per 
dm3. 
First, using a fixed complex concentration (3d = 2.00 µM; 5d = 1.25 µM) it was added 
aliquots of DNA solution ([DNA] = 3.00 mM) to the sample. The experiment was 
performed using an UV/Visible Spectrophotometer - UV380G – Gehakain, at 305 K and 
the complex-DNA solutions were allowed to incubate for 5 minutes before each spectra 
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recording. The intrinsic binding constants (Kb) of the interaction between compounds 
and DNA can be calculated using the Benesi-Hildelbrand equation: 
 

  

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  	

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where, A0 e A are the absorbances of the drug and the durg-DNA adduct, respectively. 
	
 and 	
 are the absorption coefficients of the drug and the drug–DNA adduct, 
respectively. Kb is the binding constant and it is obtained from intercept-to-slope ratios 
of a 1/(A – A0) versus 1/[DNA] plots. 
 
4.5 Docking validation 
Step 1 (VS 1): The grid box dimensions were 96x96x96 points, considering all DNA 
structure. Molecular docking genetic algorithm parameters changed from default were 
population size of 50, number of evaluation of 50000000, for 25 docking runs. 
Step 2 (VS 2): In these calculations, the re-docking of neutropsin was performed in a 
reduced grid box with dimensions of 60x70x50 points, focusing in the region of binding. 
The parameters changed of the default were population size of 50, number of 
evaluations of 25000000 and 25 docking runs. 
 
Figure 6. Molecular docking validation using re-docking of neutropsin (green), VS 1 (A) and VS 2 (B). Molecular 
docking between Hoechst-33258 (pink) and DNA using parameters of VS 1 (C) and VS 2 (D). A-T rich region in 
blue and G-C rich region in purple. 
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Highlights: 
 - A new insight of 2-phenyl-1-alkylaziridines and β-amino alcohols towards cancer cells 
 - Aziridine 5d was the most potent compound towards TNBC cell line 
 - β-amino alcohol 3f was the most active compound against MCF 7 cell line 
- The compounds induced cell death most probably via an apoptotic pathway 
 - The compounds acted via a mechanism of action found on crescent-like shape molecules 
 
